Literature DB >> 8144860

Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors.

P Colombo1, G Paganelli, P Magnani, C Songini, F Fazio, G Faglia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8144860     DOI： 10.1007/BF03348939

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  9 in total

Review 1.  Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.

Authors:  L J Deftos
Journal:  Endocr Rev       Date:  1991-05       Impact factor: 19.871

Review 2.  Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting.

Authors:  G Paganelli; M Malcovati; F Fazio
Journal:  Nucl Med Commun       Date:  1991-03       Impact factor: 1.690

Review 3.  Synaptophysin and chromogranins/secretogranins--widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis.

Authors:  B Wiedenmann; W B Huttner
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

4.  Chromogranin, an integral membrane protein.

Authors:  J Settleman; J Nolan; R H Angeletti
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

5.  Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression.

Authors:  L Jin; W F Chandler; J B Smart; B G England; R V Lloyd
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

6.  Chromogranin A and B in adenomas of the pituitary. An immunohistochemical study of 42 cases.

Authors:  K W Schmid; M Kröll; A Hittmair; H Maier; M Tötsch; R Gasser; G Finkenstett; R Hogue-Angeletti; R Fischer-Colbrie
Journal:  Am J Surg Pathol       Date:  1991-11       Impact factor: 6.394

7.  Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.

Authors:  G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

8.  Chromogranin B (secretogranin I), a secretory protein of the regulated pathway, is also present in a tightly membrane-associated form in PC12 cells.

Authors:  S W Pimplikar; W B Huttner
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

9.  Preparation and characterization of anti-human chromogranin A and chromogranin B (secretogranin I) monoclonal antibodies.

Authors:  M Pelagi; C Bisiani; A Gini; M A Bonardi; P Rosa; P Marè; G Viale; M Grazia Cozzi; M Salvadore; A Zanini
Journal:  Mol Cell Probes       Date:  1989-03       Impact factor: 2.365
  9 in total
  4 in total

1.  In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting.

Authors:  A G Siccardi; G Paganelli; A E Pontiroli; M Pelagi; P Magnani; G Viale; G Faglia; F Fazio
Journal:  Eur J Nucl Med       Date:  1996-11

2.  Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.

Authors:  G Buccheri; A Biggi; D Ferrigno; M Quaranta; A Leone; G Vassallo; F Pugno
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

3.  Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy.

Authors:  P Magnani; F Fazio; C Grana; C Songini; L Frigerio; S Pecorelli; G Mangili; N Colombo; C D Mariani; G Paganelli
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

4.  Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.

Authors:  P Magnani; G Paganelli; C Songini; A Samuel; F Sudati; A G Siccardi; F Fazio
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.